BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 26898658)

  • 1. Gut Microbiota of Nonalcoholic Fatty Liver Disease.
    Abdou RM; Zhu L; Baker RD; Baker SS
    Dig Dis Sci; 2016 May; 61(5):1268-81. PubMed ID: 26898658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gut microbiome and nonalcoholic fatty liver diseases.
    Zhu L; Baker RD; Baker SS
    Pediatr Res; 2015 Jan; 77(1-2):245-51. PubMed ID: 25310763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Buffet C
    Bull Acad Natl Med; 2014 Dec; 198(9):1641-52. PubMed ID: 27356366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
    Wree A; Geisler LJ; Tacke F
    Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
    Ghoshal UC; Goel A; Quigley EMM
    Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
    Fianchi F; Liguori A; Gasbarrini A; Grieco A; Miele L
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
    Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal microbiota and nonalcoholic steatohepatitis.
    Brandl K; Schnabl B
    Curr Opin Gastroenterol; 2017 May; 33(3):128-133. PubMed ID: 28257306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications.
    Jayakumar S; Loomba R
    Aliment Pharmacol Ther; 2019 Jul; 50(2):144-158. PubMed ID: 31149745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
    Boursier J; Diehl AM
    Clin Liver Dis; 2016 May; 20(2):263-75. PubMed ID: 27063268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of gut microbiota and metagenome with nonalcoholic fatty liver disease].
    Shen F; Fan JG
    Zhonghua Gan Zang Bing Za Zhi; 2013 Nov; 21(11):811-4. PubMed ID: 24516926
    [No Abstract]   [Full Text] [Related]  

  • 14. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.
    Meroni M; Longo M; Dongiovanni P
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31689910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol.
    Lambert JE; Parnell JA; Eksteen B; Raman M; Bomhof MR; Rioux KP; Madsen KL; Reimer RA
    BMC Gastroenterol; 2015 Dec; 15():169. PubMed ID: 26635079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease.
    Ferolla SM; Armiliato GN; Couto CA; Ferrari TC
    Nutrients; 2014 Dec; 6(12):5583-99. PubMed ID: 25479248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
    Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
    Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.
    de Faria Ghetti F; Oliveira DG; de Oliveira JM; de Castro Ferreira LEVV; Cesar DE; Moreira APB
    Eur J Nutr; 2018 Apr; 57(3):861-876. PubMed ID: 28875318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: Roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA.
    Delarue J; Lallès JP
    Mol Nutr Food Res; 2016 Jan; 60(1):147-59. PubMed ID: 26300318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.